[Erythropoiesis stimulating agents in clinical practice]
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|March 19, 2015
Summary
Anemia is common in advanced chronic kidney disease (CKD) due to iron deficiency and low erythropoietin. Treatments evolved from transfusions to recombinant erythropoietin (rHuEPO) and longer-acting agents.
Area of Science:
- Nephrology
- Hematology
Background:
- Anemia is a frequent complication in advanced chronic kidney disease (CKD).
- Key causes include iron deficiency and reduced erythropoietin production by the kidneys.
Purpose of the Study:
- To review the evolution of anemia treatment in CKD patients.
- To highlight advancements from blood transfusions to modern pharmacotherapy.
Main Methods:
- Literature review of anemia management in CKD.
- Focus on the historical progression of therapeutic options.
Main Results:
- Treatment options for anemia in CKD have significantly advanced.
- Recombinant human erythropoietin (rHuEPO) revolutionized management.
- Longer-acting agents like darbepoetin alfa and methoxy polyethylene glycol-epoetin beta offer improved convenience.
Conclusions:
- Modern treatments for CKD-related anemia are more effective and diverse.
- rHuEPO and its analogues represent major therapeutic progress.
More Related Videos
Related Concept Videos
01:24Factors Affecting Erythropoiesis
8.7K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
8.7K
01:14Erythropoiesis
7.0K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
7.0K
01:14Erythropoiesis
4.2K
4.2K
01:28Role of Hematopoietic Growth Factors
4.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
4.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
621
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
621
01:01Regulation of Hematopoietic Stem Cells
4.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.5K